Definium Therapeutics, Inc. (DFTX)
NASDAQ: DFTX · Real-Time Price · USD
22.48
-0.78 (-3.35%)
At close: Apr 24, 2026, 4:00 PM EDT
22.47
-0.01 (-0.03%)
After-hours: Apr 24, 2026, 7:59 PM EDT
Definium Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts that cover Definium Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $38.5, which forecasts a 71.26% increase in the stock price over the next year. The lowest target is $25 and the highest is $70.
Price Target: $38.5 (+71.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Definium Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|
| Strong Buy | 1 | 2 | 4 |
| Buy | 2 | 2 | 4 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 3 | 4 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Maintains $23 → $30 | Buy | Maintains | $23 → $30 | +33.45% | Apr 22, 2026 |
| Stifel | Stifel | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +33.45% | Apr 17, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $38 | Strong Buy | Maintains | $25 → $38 | +69.04% | Apr 16, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $49 | Buy | Initiates | $49 | +117.97% | Apr 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $55 → $70 | Strong Buy | Maintains | $55 → $70 | +211.39% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
31.74M
EPS This Year
-1.99
from -2.06
EPS Next Year
-1.82
from -1.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 200.0M | ||||||
| Avg | n/a | 31.7M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.68 | -0.56 | ||||||
| Avg | -1.99 | -1.82 | ||||||
| Low | -2.45 | -2.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.